SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-19-064066
Filing Date
2019-11-14
Accepted
2019-11-14 14:45:48
Documents
1
Group Members
VERSANT SIDE FUND IV, L.P.VERSANT VANTAGE I GP, L.P.VERSANT VANTAGE I GP-GP, LLCVERSANT VANTAGE I, L.P.VERSANT VENTURE CAPITAL IV, L.P.VERSANT VENTURES IV, LLCVERSANT VENTURES VI GP, L.P.VERSANT VENTURES VI GP-GP, LLC

Document Format Files

Seq Description Document Type Size
1 SC 13D a19-22914_1sc13d.htm SC 13D 313336
  Complete submission text file 0001104659-19-064066.txt   315224
Mailing Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 (415) 801-8100
Versant Venture Capital VI, L.P. (Filed by) CIK: 0001687880 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D

Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Subject) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91186 | Film No.: 191219118
SIC: 2836 Biological Products, (No Diagnostic Substances)